Company data sheet · Eli Lilly
Eli Lilly: growth far beyond its economy.
- Industry
- Pharmaceutical Preparations Manufacturing
- Headquarters
- United States
- Ticker
- LLY (NYSE)
- Sources
- SEC filings (1994–2026), Stratrix's verified Decision Cases, market data and official economic statistics for the United States
- Data as of
- October 18, 2026
- It outgrew its own economy many times over. Revenue rose from $21.2 billion in 2016 to $65.2 billion in 2025: 3.1 times as much. The US economy, counted the same way in money terms, grew about 60%. Whatever drove it, the economy around it does not account for growth of that size.
- Ahead of almost everyone like it. From 2016 to 2025, its revenue grew 256% in US dollars; the median among 181 large manufacturers grew 49%. It outgrew 92% of them.
- Four decisions on record. Stratrix has verified four of Eli Lilly's big decisions, each with what happened next. The best: "Eli Lilly Cut Insulin 70% and Got Richer. The Charity Was the Strategy", 144 points ahead of the S&P 500 over the next three years.
Financial results
| Fiscal year | Revenue | Net income | |
|---|---|---|---|
| 2016 | $21.2 billion | $2.7 billion | |
| 2017 | $20 billion | −$0.2 billion | |
| 2018 | $21.5 billion | $3.2 billion | |
| 2019 | $22.3 billion | $8.3 billion | |
| 2020 | $24.5 billion | $6.2 billion | |
| 2021 | $28.3 billion | $5.6 billion | |
| 2022 | $28.5 billion | $6.2 billion | |
| 2023 | $34.1 billion | $5.2 billion | |
| 2024 | $45 billion | $10.6 billion | |
| 2025 | $65.2 billion | $20.6 billion |
As reported in its annual filings. Losses in red.
Stratrix Decision Cases
- 2025Lilly Sells the Same Drug at $1,086 and $299. The Gap Is the Strategy.
- 2023Eli Lilly Cut Insulin 70% and Got Richer. The Charity Was the Strategy.
- 2022Lilly's Obesity Windfall Is Real. The 18-Month Head Start Behind It Is the Part Nobody Mentions.
- 2020Eli Lilly Started Building Tirzepatide Factories in 2020, Years Before Any FDA Approval
The full data sheet · Data Plan
Everything behind these findings, ready for your board deck.
- Market reaction to disclosed decisions: 23 decision filings since 2016, each linked to the SEC, with the share return against its sector and the S&P 500 the next day and the next year (22 with market data).
- Economic context: 7 measures for the United States, every year since 2016, from the official sources.
- Peer comparison: against 264 companies of its size in its sector.
- Financial results: ten years of revenue, operating and net income, and every annual report, linked.
- Methods and sources, so each number can be checked and cited.
The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.